Regulus Therapeutics Inc. (NASDAQ:RGLS) presented updated interim HCV data on Friday from a 79-patient Phase II trial of a four-week regimen of RG-101 plus a direct-acting antiviral (DAA). The company shed $0.90
Read the full 324 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury